Cargando…

Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study

BACKGROUND: World Health Organization (WHO) grade IV glioma remains one of the most lethal tumors with a dismal prognosis and inevitable recurrence. We evaluated the safety and efficacy of immunotherapy with radiotherapy in this population of patients. METHODS: This study was a single-arm, open-labe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Haihui, Yu, Kefu, Cui, Yong, Ren, Xiaohui, Li, Mingxiao, Yang, Chuanwei, Zhao, Xuzhe, Zhu, Qinghui, Lin, Song
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138184/ https://www.ncbi.nlm.nih.gov/pubmed/34025640 http://dx.doi.org/10.3389/fimmu.2021.632547

Ejemplares similares

Nomograms for predicting cancer-specific survival in patients with primary central nervous system lymphoma: a population-based analysis
por: Yang, Chuanwei, et al.
Publicado: (2021)

Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma
por: Jiang, Haihui, et al.
Publicado: (2021)

Classification of Progression Patterns in Glioblastoma: Analysis of Predictive Factors and Clinical Implications
por: Jiang, Haihui, et al.
Publicado: (2020)

Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features
por: Li, Mingxiao, et al.
Publicado: (2021)

Corrigendum: Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological and Molecular Features
por: Li, Mingxiao, et al.
Publicado: (2021)

Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series
por: Yang, Chuanwei, et al.
Publicado: (2022)

Combining MGMT promoter pyrosequencing and protein expression to optimize prognosis stratification in glioblastoma
por: Li, Mingxiao, et al.
Publicado: (2021)

Characterization and clinical implications of different malignant transformation patterns in diffuse low‐grade gliomas
por: Jiang, Haihui, et al.
Publicado: (2023)

Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas
por: Li, Mingxiao, et al.
Publicado: (2022)

Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy
por: Teng, Chubei, et al.
Publicado: (2022)

A prognostic estimation model based on mRNA-sequence data for patients with oligodendroglioma
por: Zhu, Qinghui, et al.
Publicado: (2022)

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy
por: Chuntova, Pavlina, et al.
Publicado: (2019)

Mechanistic rationales for combining immunotherapy with radiotherapy
por: Chi, Alexander, et al.
Publicado: (2023)

T2/FLAIR Abnormity Could be the Sign of Glioblastoma Dissemination
por: Li, Mingxiao, et al.
Publicado: (2022)

Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors
por: Ji, Xiaoqin, et al.
Publicado: (2023)

Immunotherapy for malignant glioma
por: Suryadevara, Carter M., et al.
Publicado: (2015)

Immunotherapies for Malignant Glioma
por: Boussiotis, Vassiliki A., et al.
Publicado: (2017)

Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?
por: Yuce Sari, Sezin, et al.
Publicado: (2021)

Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas
por: Yang, Kaiyuan, et al.
Publicado: (2019)

Immunotherapy: a promising approach for glioma treatment
por: Yasinjan, Feroza, et al.
Publicado: (2023)

Next-Generation Anti-Angiogenic Therapies as a Future Prospect for Glioma Immunotherapy; From Bench to Bedside
por: Shamshiripour, Parisa, et al.
Publicado: (2022)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020)

Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies
por: Li, Haosheng, et al.
Publicado: (2022)

Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
por: Zeng, Jiayi, et al.
Publicado: (2021)

Deciphering the role of QPCTL in glioma progression and cancer immunotherapy
por: Liu, Yu’e, et al.
Publicado: (2023)

Pre-clinical models for evaluating glioma targeted immunotherapies
por: Frederico, Stephen C., et al.
Publicado: (2023)

Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
por: Goedegebuure, Ruben S. A., et al.
Publicado: (2019)

Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer
por: Jie, Chen, et al.
Publicado: (2023)

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma
por: Yan, Dongming, et al.
Publicado: (2022)

DDOST Correlated with Malignancies and Immune Microenvironment in Gliomas
por: Chang, Xiaojing, et al.
Publicado: (2022)

Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
por: Zheng, Yiwen, et al.
Publicado: (2023)

Glioma Stem Cells and Immunotherapy for the Treatment of Malignant Gliomas
por: Toda, Masahiro
Publicado: (2013)

Concurrent immunotherapy and re‐irradiation utilizing stereotactic body radiotherapy for recurrent high‐grade gliomas
por: Mahase, Sean S., et al.
Publicado: (2023)

Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?
por: Roerden, Malte, et al.
Publicado: (2019)

γδ T cells in immunotherapies for B-cell malignancies
por: Rimailho, Léa, et al.
Publicado: (2023)

Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?
por: Martin-Romano, Patricia, et al.
Publicado: (2021)

Functional characterization of TSPAN7 as a novel indicator for immunotherapy in glioma
por: Chen, Long, et al.
Publicado: (2023)

Diabetic complications and prospective immunotherapy
por: Reynolds, Lewis, et al.
Publicado: (2023)

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
por: Meng, Lu, et al.
Publicado: (2021)

Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer
por: Eckert, Franziska, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7cb9i0l5mtdema51cg0cgloimp